Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Journey Medical CorporationNASDAQ: DERM
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to -14.0%
Net margin was -14.0% in Q1 FY2026, up 17.0 pp from a year earlier. On a trailing-twelve-month basis it was -14.8%, down 0.1 pp year over year. Over 3 fiscal years it widened by 21.7 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 2 analysts of -5.3% for the fiscal year ending Dec 2026, up from -18.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -14.0%-6.2 pp QoQ
- Last fiscal yearDec 2025
- -18.5%+7.7 pp YoY
- LTMMar 2026
- -14.8%-0.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.0 pp | +21.9 pp | +4.8 pp |
| 1 year | +7.7 pp | +13.2 pp | +5.5 pp |
| 3 years | +21.7 pp | +27.1 pp | +5.4 pp |
| 5 years | +34.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -18.5%
- Year-over-year change
- +7.7pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -18.5% | +7.7pp |
| FY2024 | 2024-12-31 | -26.1% | -21.3pp |
| FY2023 | 2023-12-31 | -4.9% | +35.4pp |
| FY2022 | 2022-12-31 | -40.2% | +29.5pp |
| FY2021 | 2021-12-31 | -69.7% | — |
Net Margin vs competitors
How DERM compares with its peers on the latest reported figures
- DERM's LTM Mar 2026 net margin of -14.8% is the 2nd highest of the 10 companies compared; the peer median is -180.3%.
- Its year-over-year change of -0.1 pp is the 5th highest of 10, against a peer median of -17.9 pp.
- Over three fiscal years its change of +21.7 pp compares with a peer median of +29.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -9.2% | -17.9 pp | — | |
| LTM Mar 2026 | -14.8% | -0.1 pp | +21.7 pp | |
| LTM Mar 2026 | -16.4% | +30.3 pp | +1523.1 pp | |
| LTM Mar 2026 | -66.4% | -46.7 pp | -55.3 pp | |
| LTM Mar 2026 | -167.0% | +2130.9 pp | +793.9 pp | |
| LTM Mar 2026 | -180.3% | -69.8 pp | -66.8 pp | |
| LTM Mar 2026 | -527.8% | +1069.7 pp | +113.4 pp | |
| LTM Mar 2026 | -1427.1% | +1583.0 pp | +1108.5 pp | |
| FY2025 | -7587.8% | -5585.1 pp | -7142.2 pp | |
| LTM Mar 2026 | -8550.6% | -8438.5 pp | -4690.6 pp | |
| Peer median (excluding DERM) | -180.3% | -17.9 pp | +29.0 pp | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.13M | 73.67M | 79.18M | 56.13M | 61.86M |
| Cost of Revenue | 32.08M | 30.78M | 26.66M | 20.88M | 25.18M |
| Gross Profit | 31.05M | 42.89M | 52.52M | 35.26M | 36.68M |
| Gross Margin | 49.2% | 58.2% | 66.3% | 62.8% | 59.3% |
| Research & Development | 16.56M | 10.94M | 7.54M | 9.86M | 480K |
| Selling, General & Admin | 39.83M | 59.47M | 43.91M | 40.2M | 44.37M |
| Operating Expenses | 65.93M | 70.41M | 54.59M | 48.93M | 44.85M |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.52M | 4.35M |
| EBITDA | (32.77M) | (23.18M) | 1.92M | (8.4M) | (3.33M) |
| EBITDA Margin | -51.9% | -31.5% | 2.4% | -15.0% | -5.4% |
| Operating Income | (34.88M) | (27.52M) | (2.07M) | (13.68M) | (8.17M) |
| Operating Margin | -55.2% | -37.4% | -2.6% | -24.4% | -13.2% |
| Interest Income | 2K | 60K | 322K | 757K | 589K |
| Interest Expense | 7.03M | 2.02M | 1.7M | 2.7M | 3.7M |
| Other Income / Expenses | (7.48M) | (2.05M) | (1.56M) | (934K) | (3.2M) |
| Income Before Tax | (42.36M) | (29.57M) | (3.63M) | (14.61M) | (11.37M) |
| Pre-Tax Margin | -67.1% | -40.1% | -4.6% | -26.0% | -18.4% |
| Income Tax Expense | 1.63M | 63K | 221K | 61K | 60K |
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Net Margin | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| EPS (Basic) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| EPS (Diluted) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| Weighted Avg Shares | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
| Weighted Avg Shares (Diluted) | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.